Bioheart, Inc. (BHRT) Promoting Growth with Unique Combination of Revenue-Generating Capabilities and Promising Product Pipeline
Bioheart, Inc. (OTCQB: BHRT) is an emerging enterprise in the regenerative medicine industry focused on the discovery, development and commercialization of cell-based therapeutics that prevent, treat or cure cardiovascular diseases. The company’s leading product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function in patients with severe heart damage due to a heart attack. In January, Bioheart announced plans to initiate phase III clinical studies of the candidate for the treatment of chronic heart failure in the coming months. Currently, Bioheart is aiming to achieve market approval for MyoCell in 2019. According to the…